{"id":"W3108175435","doi":"10.1136/esmoopen-2020-001081","title":"Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Daiichi Sankyo Europe; Servier; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Eisai; Symphogen; Pfizer; Incyte; BeiGene; Agios Pharmaceuticals; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Huntsman Cancer Institute; Sierra Oncology; King Abdullah International Medical Research Center; Eli Lilly and Company; U.S. Department of Defense; Sanofi; Exelixis; GlaxoSmithKline; Celgene; Bristol-Myers Squibb; AstraZeneca; Spectrum Pharmaceuticals; Amgen","keywords":"Dosing; Medicine; Phase (matter); Internal medicine; Oncology; Chemistry","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004172629,0.0001671461,0.000283386,0.00002925755,0.00008895831,0.0001100779,0.0008149542,0.00002230812,0.0000482109],"category_scores_gemma":[0.0002759514,0.0001050762,0.00001210582,0.0002341088,0.00006464101,0.00002917839,0.001546177,0.0001175399,0.000005234317],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001843963,"about_ca_system_score_gemma":0.0001424925,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002089055,"about_ca_topic_score_gemma":0.0004361826,"domain_scores_codex":[0.9984648,0.0002825519,0.0002737271,0.0004432375,0.0002603388,0.0002753641],"domain_scores_gemma":[0.9992911,0.00004305262,0.00007542301,0.0003194968,0.000121322,0.0001496473],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.2846147,0.02872645,0.2891255,0.00041608,0.001987548,0.0001839745,0.02725886,0.007866865,0.3127788,0.00003578142,0.001776638,0.04522876],"study_design_scores_gemma":[0.25268,0.09981943,0.3382676,0.0005321242,0.000381093,0.000008248256,0.01407299,0.004459829,0.2854757,0.00000912592,0.002674395,0.001619399],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952938,0.00002194565,0.00007958686,0.0004314666,0.00001556646,0.004008692,0.00005647017,0.000002522136,0.00008996475],"genre_scores_gemma":[0.996774,0.000006542446,0.002784425,0.0002225975,0.000009265637,0.00007456095,0.00004914546,0.0000273562,0.00005212454],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07109298,"threshold_uncertainty_score":0.4284884,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04774679406852019,"score_gpt":0.3900613635071492,"score_spread":0.342314569438629,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}